MedDataX Logo

Proteiomic Fingerprints of Gastric Juice

NCT ID: NCT00834236

Last Updated: 2015-12-07

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

76 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-03-31

Study Completion Date

2011-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

No accurate, inexpensive and non-invasive test for gastric cancer screening is currently available. The investigators' recent study identified a1-antitrypsin and other proteins as potential biomarkers of gastric cancer in gastric juice. The aim of this study was to develop a novel non-invasive modality for detecting gastric cancer by measurement of biomarkers in gastric juice.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients and methods: The study consisted of two parts: (1) investigating the differences in gastric juice biomarker concentrations between gastric cancer patients and controls, and (2) screening gastric cancer using string test to obtain gastric juice followed by immunoassay for biomarker concentration.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastric Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

gastric cancer

gastric cancer patients

Group Type EXPERIMENTAL

normal subject

Intervention Type OTHER

biomarker in gastric juice, i.e., alpha 1-antitrypsin, CEA

gastric cancer

Intervention Type OTHER

biomarker in gastric juice, e.g., alpha 1-antitrypsin

normal subject

healthy subject

Group Type ACTIVE_COMPARATOR

normal subject

Intervention Type OTHER

biomarker in gastric juice, i.e., alpha 1-antitrypsin, CEA

gastric cancer

Intervention Type OTHER

biomarker in gastric juice, e.g., alpha 1-antitrypsin

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

normal subject

biomarker in gastric juice, i.e., alpha 1-antitrypsin, CEA

Intervention Type OTHER

gastric cancer

biomarker in gastric juice, e.g., alpha 1-antitrypsin

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

biomarker in gastric juice biomarker in gastric juice

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* healthy subjects and gastric cancer patients documented by endoscopy.

Exclusion Criteria

* the use of proton pump inhibitors or histamine-2 receptor antagonists within 4 weeks prior to the study
* coexistence of two kinds of gastroduodenal lesions
* coexistence of severe systemic diseases
Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Science and Technology Council, Taiwan

OTHER_GOV

Sponsor Role collaborator

Kaohsiung Veterans General Hospital.

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ping-I (William) Hsu, M.D.

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ping-I Hsu, M.D.

Role: PRINCIPAL_INVESTIGATOR

Kaohsiung Veterans Genaral hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Kaohsiung Veterans General Hospital

Kaohsiung City, Kaohsiung, Taiwan

Site Status

Kaohsiung Veterans General Hospital

Kaohsiung City, , Taiwan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Taiwan

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

VGHKS96-CT2-24

Identifier Type: -

Identifier Source: org_study_id